In vivo induction of HPV 16 specific cytotoxic ctl and T-helper immunity in patients with advanced cervical cancer using autologous dendritic cells (dc) pulsed with tumour lysate as a potential anti-cancer vaccine

Adams, Mary; Jong, Annemieke de; Navabi, H.; Lippetz, C.; Jasani, Bharat; Man, Stephen; Fiander, Alison; Wood, Ronald; Berg, Sabine; Mason, Malcolm David

doi:10.1016/s0959-8049(01)81515-x

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DCs were prepared as autologous vaccines for the patients, and the patients received six weekly subcutaneous injections. CTL responses were generated in some patients, and the DCs were well tolerated by their original donor (148). Other clinical trials have employed a similar strategies (149).…”

Section: Dendritic Cell-based Vaccinesmentioning

confidence: 99%

Vaccines against human papillomavirus

Lin

Alphs

Hung³

et al. 2007

Front Biosci

View full text Add to dashboard Cite

Human papillomavirus has been identified as an etiological factor for cervical cancer, anogenital cancers and a subset of head and neck cancers. These important observations suggest that HPV vaccines have potential in the prevention and treatment of cervical cancer and other HPV-associated malignancies. The HPV genome encodes two HPV late genes, L1 and L2, which form the viral capsid. Early viral proteins support viral genome replication, two of which (E6 and E7) are important for HPV associated malignant transformation. Prophylactic HPV vaccines prevent infection by inducing neutralizing antibodies against HPV capsid proteins L1 and L2. However, because HPV-infected basal keratinocytes and HPV-transformed cells generally do not express L1 or L2, therapeutic HPV vaccines aim to treat established HPV infections and HPV-associated malignancies by targeting non-structural early viral antigens of HPV such as E6 and E7. Results from preclinical HPV vaccine studies have led to several HPV vaccine clinical trials. If these prophylactic and therapeutic HPV vaccines prove as successful in patients as they have in animal models, vaccination may provide for control and eventually eradication of oncogenic HPV infection and HPV-related cancers.

show abstract

Section: Dendritic Cell-based Vaccinesmentioning

confidence: 99%

Vaccines against human papillomavirus

Lin

Alphs

Hung³

et al. 2007

Front Biosci

View full text Add to dashboard Cite

show abstract

“…In the clinic, a recombinant vaccinia vector encoding an HPV‐16/18 E6/E7 fusion protein, termed TA‐HPV, has been evaluated in several phase I/II trials. It was well tolerated and induced T‐cell responses in patients with CIN (101–103) and also VIN (104, 105) and VAIN (106). In an uncontrolled study in VAIN patients vaccinated with TA‐HPV, five out of 12 patients showed at least a 50% reduction in lesion diameter over a 24‐week period, and one patient showed complete regression of their disease (106).…”

Section: Approaches To Immunotherapymentioning

confidence: 99%

Antigen‐specific immunotherapy of cervical and ovarian cancer

Hung¹,

Monie³

et al. 2008

Immunological Reviews

View full text Add to dashboard Cite

We contrast the efforts to treat ovarian cancer and cervical cancer through vaccination because of their different pathobiology. A plethora of approaches have been developed for therapeutic vaccination against cancer, many of which target defined tumor-associated antigens (TAAs). Persistent infection with oncogenic human papillomavirus (HPV) types causes cervical cancer. Furthermore, cervical cancer patients frequently mount both humoral and T-cell immune responses to the HPV E6 and E7 oncoproteins, whose expression is required for the transformed phenotype. Numerous vaccine studies target these viral TAAs, including recent trials that may enhance clearance of pre-malignant disease. By contrast, little is known about the etiology of epithelial ovarian cancer. Although it is clear that p53 mutation or loss is a critical early event in the development of epithelial ovarian cancer, no precursor lesion has been described for the most common serous histotype, and even the location of its origin is debated. These issues have complicated the selection of appropriate ovarian TAAs and the design of vaccines. Here we focus on mesothelin as a promising ovarian TAA, because it is overexpressed and immunogenic at high frequency in patients, is displayed on the cell surface, and potentially contributes to ovarian cancer biology.

show abstract